UNMET NEED FOR DKD TREATMENT OPTIONS IN T1DM Despite advancements in the management of type 1 diabetes mellitus (T1D), there remains a significant unmet need for effective therapeutic options that address both glycaemic control and associated complications, particularly DKD
The BMJ reported the generic approval was made possible after Novo Nordisk did not pay a C$250 annual fee [Source: bmj.com/content/393/bmj-2026-597166]
GLP-1 (glucagon-like peptide-1) receptor agonists are medications designed to regulate blood sugar, reduce appetite, and slow digestion
Additionally, an attorney will have experience gathering and presenting evidence of harm and can help you navigate your way through the legal process
Understanding the side effect profiles of emerging GLP-1 compounds will help women make informed choices as more options reach the market
400+ board certified Join Mochi Pricing Exceptional care, made easier to access Mochi membership brings together provider access, coaching, support, and treatment options in one guided experience